Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus

Richard A Preston, Neyton M. Baltodano, Alberto B. Alonso, Murray Epstein

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Both ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) are renoprotective beyond their effects on blood pressure (BP), but their widespread use is limited by their tendency to provoke hyperkalemia. The comparative effects of ACEI and ARB on potassium handling have not been investigated. The objective of this study was to determine whether there are differences in dynamic renal potassium handling between ACEI and ARB in response to an tassium challenge. This was a randomized crossover study of candesartan versus lisinopril titrated to control BP followed by an inpatient study of renal potassium handling in 24 hypertensive patients with type II diabetes mellitus (DM II) and preserved renal function. Following an oral potassium challenge (0.75 mmol/kg), differences in hourly serum K (mmol/L), rate of urinary potassium excretion (UkV micromol/min), and fractional excretion of potassium (FEK) were assessed by repeated-measures ANOVA. Hourly UkV (p =.45) and FEK (p =.19) were similar for candesartan and lisinopril, although FEK at 2 hours for candesartan tended to exceed that for lisinopril (. 34 [.04] vs..26 [.03]) and approached significance (p = .096). UkV for candesartan at hour 2 was 177 (26) and 121 (21) for lisinopril and also approached significance (p =.10). Serial serum potassium did not differ (p =.70). No statistical differences were discovered in renal potassium handling between candesartan and lisinopril in patients with DM II and preserved renal function. Whether there are differences between the drug classes in renal impairment remains to be determined.

Original languageEnglish
Pages (from-to)754-761
Number of pages8
JournalJournal of Clinical Pharmacology
Volume42
Issue number7
DOIs
StatePublished - Jul 2 2002

Fingerprint

Angiotensin Receptors
Type 2 Diabetes Mellitus
Lisinopril
Potassium
Kidney
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Hyperkalemia
Renal Elimination
Serum
Cross-Over Studies
Inpatients
Analysis of Variance
candesartan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. / Preston, Richard A; Baltodano, Neyton M.; Alonso, Alberto B.; Epstein, Murray.

In: Journal of Clinical Pharmacology, Vol. 42, No. 7, 02.07.2002, p. 754-761.

Research output: Contribution to journalArticle

@article{ef653bcfe38f40c3bcbdf4e7433acb62,
title = "Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus",
abstract = "Both ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) are renoprotective beyond their effects on blood pressure (BP), but their widespread use is limited by their tendency to provoke hyperkalemia. The comparative effects of ACEI and ARB on potassium handling have not been investigated. The objective of this study was to determine whether there are differences in dynamic renal potassium handling between ACEI and ARB in response to an tassium challenge. This was a randomized crossover study of candesartan versus lisinopril titrated to control BP followed by an inpatient study of renal potassium handling in 24 hypertensive patients with type II diabetes mellitus (DM II) and preserved renal function. Following an oral potassium challenge (0.75 mmol/kg), differences in hourly serum K (mmol/L), rate of urinary potassium excretion (UkV micromol/min), and fractional excretion of potassium (FEK) were assessed by repeated-measures ANOVA. Hourly UkV (p =.45) and FEK (p =.19) were similar for candesartan and lisinopril, although FEK at 2 hours for candesartan tended to exceed that for lisinopril (. 34 [.04] vs..26 [.03]) and approached significance (p = .096). UkV for candesartan at hour 2 was 177 (26) and 121 (21) for lisinopril and also approached significance (p =.10). Serial serum potassium did not differ (p =.70). No statistical differences were discovered in renal potassium handling between candesartan and lisinopril in patients with DM II and preserved renal function. Whether there are differences between the drug classes in renal impairment remains to be determined.",
author = "Preston, {Richard A} and Baltodano, {Neyton M.} and Alonso, {Alberto B.} and Murray Epstein",
year = "2002",
month = "7",
day = "2",
doi = "10.1177/009127002401102696",
language = "English",
volume = "42",
pages = "754--761",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus

AU - Preston, Richard A

AU - Baltodano, Neyton M.

AU - Alonso, Alberto B.

AU - Epstein, Murray

PY - 2002/7/2

Y1 - 2002/7/2

N2 - Both ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) are renoprotective beyond their effects on blood pressure (BP), but their widespread use is limited by their tendency to provoke hyperkalemia. The comparative effects of ACEI and ARB on potassium handling have not been investigated. The objective of this study was to determine whether there are differences in dynamic renal potassium handling between ACEI and ARB in response to an tassium challenge. This was a randomized crossover study of candesartan versus lisinopril titrated to control BP followed by an inpatient study of renal potassium handling in 24 hypertensive patients with type II diabetes mellitus (DM II) and preserved renal function. Following an oral potassium challenge (0.75 mmol/kg), differences in hourly serum K (mmol/L), rate of urinary potassium excretion (UkV micromol/min), and fractional excretion of potassium (FEK) were assessed by repeated-measures ANOVA. Hourly UkV (p =.45) and FEK (p =.19) were similar for candesartan and lisinopril, although FEK at 2 hours for candesartan tended to exceed that for lisinopril (. 34 [.04] vs..26 [.03]) and approached significance (p = .096). UkV for candesartan at hour 2 was 177 (26) and 121 (21) for lisinopril and also approached significance (p =.10). Serial serum potassium did not differ (p =.70). No statistical differences were discovered in renal potassium handling between candesartan and lisinopril in patients with DM II and preserved renal function. Whether there are differences between the drug classes in renal impairment remains to be determined.

AB - Both ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) are renoprotective beyond their effects on blood pressure (BP), but their widespread use is limited by their tendency to provoke hyperkalemia. The comparative effects of ACEI and ARB on potassium handling have not been investigated. The objective of this study was to determine whether there are differences in dynamic renal potassium handling between ACEI and ARB in response to an tassium challenge. This was a randomized crossover study of candesartan versus lisinopril titrated to control BP followed by an inpatient study of renal potassium handling in 24 hypertensive patients with type II diabetes mellitus (DM II) and preserved renal function. Following an oral potassium challenge (0.75 mmol/kg), differences in hourly serum K (mmol/L), rate of urinary potassium excretion (UkV micromol/min), and fractional excretion of potassium (FEK) were assessed by repeated-measures ANOVA. Hourly UkV (p =.45) and FEK (p =.19) were similar for candesartan and lisinopril, although FEK at 2 hours for candesartan tended to exceed that for lisinopril (. 34 [.04] vs..26 [.03]) and approached significance (p = .096). UkV for candesartan at hour 2 was 177 (26) and 121 (21) for lisinopril and also approached significance (p =.10). Serial serum potassium did not differ (p =.70). No statistical differences were discovered in renal potassium handling between candesartan and lisinopril in patients with DM II and preserved renal function. Whether there are differences between the drug classes in renal impairment remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0035998751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035998751&partnerID=8YFLogxK

U2 - 10.1177/009127002401102696

DO - 10.1177/009127002401102696

M3 - Article

VL - 42

SP - 754

EP - 761

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -